Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 57 articles: HTML format

Single Articles

November 2021
1. CALDEIRA D, Pinto FJ
   COVID-19 and myocardial infarction.
   Lancet. 2021;398:1963-1964.
   PubMed    
   
   
   
2. KATSOULARIS I, Fonseca-Rodriguez O, Farrington P, Lindmark K, et al
   COVID-19 and myocardial infarction - Authors' reply.
   Lancet. 2021;398:1964.
   PubMed    
   
   
   
3. SABATINE MS, Bergmark BA, Murphy SA, O'Gara PT, et al
   Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
   Lancet. 2021 Nov 12. pii: S0140-6736(21)02334.
   PubMed     Abstract available
   
   
   
4. MEHRAN R, Owen R, Chiarito M, Baber U, et al
   A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.
   Lancet. 2021 Nov 12. pii: S0140-6736(21)02326.
   PubMed     Abstract available
   
   
   
5. BELLEY-COTE EP, Devereaux PJ
   PCI versus CABG for left main coronary artery disease: is the jury still out?
   Lancet. 2021 Nov 12. pii: S0140-6736(21)02491.
   PubMed    
   
   
   
6. KANG J, Koo BK, Park KW, Shin ES, et al
   Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply.
   Lancet. 2021;398:1685-1686.
   PubMed    
   
   
   
7. PAREEK M, Byrne C
   Aspirin versus clopidogrel after percutaneous coronary intervention.
   Lancet. 2021;398:1685.
   PubMed    
   
   
   
8. BYRNE RA, McGovern L
   Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once.
   Lancet. 2021 Nov 3. pii: S0140-6736(21)02397.
   PubMed    
   
   
   
9. XU B, Tu S, Song L, Jin Z, et al
   Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
   Lancet. 2021 Nov 3. pii: S0140-6736(21)02248.
   PubMed     Abstract available
   
   
   October 2021
10. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    PubMed     Abstract available
    
    
    
11. KIM CJ, Park MW, Kim MC, Choo EH, et al
    Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised tr
    Lancet. 2021;398:1305-1316.
    PubMed     Abstract available
    
    
    
12. TSAMPASIAN V, Maart C, Vassiliou VS, Garg P, et al
    Mitral valve disease in sarcoidosis diagnosed by cardiovascular magnetic resonance.
    Lancet. 2021;398:1358.
    PubMed    
    
    
    September 2021
13. PINTO FJ, Pineiro D, Banerjee A, Perel P, et al
    World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease.
    Lancet. 2021 Sep 28. pii: S0140-6736(21)02144.
    PubMed    
    
    
    
14. SINGH JA
    Cardiovascular safety of febuxostat.
    Lancet. 2021;398:955.
    PubMed    
    
    
    
15. MACDONALD TM, Nuki G, Robertson M, Ford I, et al
    Cardiovascular safety of febuxostat - Authors' reply.
    Lancet. 2021;398:955-956.
    PubMed    
    
    
    
16. XU C
    Cardiovascular safety of febuxostat.
    Lancet. 2021;398:954-955.
    PubMed    
    
    
    August 2021
17. JOSEPH P, Roshandel G, Gao P, Pais P, et al
    Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01827.
    PubMed     Abstract available
    
    
    
18. MANT J, McManus R
    Polypills with or without aspirin for primary prevention of cardiovascular disease.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01913.
    PubMed    
    
    
    
19. 
    Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available
    
    
    
20. TZOLOS E, Bing R, Newby DE, Dweck MR, et al
    Categorising myocardial infarction with advanced cardiovascular imaging.
    Lancet. 2021;398:e9.
    PubMed    
    
    
    July 2021
21. KATSOULARIS I, Fonseca-Rodriguez O, Farrington P, Lindmark K, et al
    Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study.
    Lancet. 2021 Jul 29. pii: S0140-6736(21)00896.
    PubMed     Abstract available
    
    
    
22. MAFHAM M, Baigent C
    What is the association of COVID-19 with heart attacks and strokes?
    Lancet. 2021 Jul 29. pii: S0140-6736(21)01071.
    PubMed    
    
    
    
23. AL-JABI SW, Aldabe L, Alhaj-Asaad L, Thaher M, et al
    Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory.
    Lancet. 2021;398 Suppl 1:S8.
    PubMed     Abstract available
    
    
    
24. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    PubMed     Abstract available
    
    
    June 2021
25. ARNETT DK
    Widespread diabetes screening for cardiovascular disease risk estimation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00764.
    PubMed    
    
    
    
26. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00572.
    PubMed     Abstract available
    
    
    May 2021
27. CHRISTOFFERSEN M, Tybjaerg-Hansen A
    Targeting IL-6 in patients at high cardiovascular risk.
    Lancet. 2021 May 14. pii: S0140-6736(21)00985.
    PubMed    
    
    
    
28. KOO BK, Kang J, Park KW, Rhee TM, et al
    Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)01063.
    PubMed     Abstract available
    
    
    
29. CHIARITO M, Stefanini GG
    Antiplatelet therapy for secondary prevention of cardiovascular disease: challenging the certainties.
    Lancet. 2021 May 14. pii: S0140-6736(21)01120.
    PubMed    
    
    
    
30. LANE R
    Roxana Mehran: driving force in women's cardiovascular health.
    Lancet. 2021 May 14. pii: S0140-6736(21)01100.
    PubMed    
    
    
    
31. VOGEL B, Acevedo M, Appelman Y, Bairey Merz CN, et al
    The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.
    Lancet. 2021 May 14. pii: S0140-6736(21)00684.
    PubMed     Abstract available
    
    
    
32. MOCUMBI AO
    Women's cardiovascular health: shifting towards equity and justice.
    Lancet. 2021 May 14. pii: S0140-6736(21)01017.
    PubMed    
    
    
    
33. 
    Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available
    
    
    
34. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.
    PubMed    
    
    
    April 2021
35. SIBBING D, Kastrati A
    Guided P2Y12 inhibitor therapy after percutaneous coronary intervention.
    Lancet. 2021;397:1423-1425.
    PubMed    
    
    
    
36. GALLI M, Benenati S, Capodanno D, Franchi F, et al
    Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Lancet. 2021;397:1470-1483.
    PubMed     Abstract available
    
    
    March 2021
37. LONNEBAKKEN MT
    The risk of no risk in STEMI.
    Lancet. 2021;397:1039-1040.
    PubMed    
    
    
    
38. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available
    
    
    
39. ERLINGE D, Maehara A, Ben-Yehuda O, Botker HE, et al
    Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
    Lancet. 2021;397:985-995.
    PubMed     Abstract available
    
    
    February 2021
40. TAKAHASHI K, van Klaveren D, Steyerberg EW, Onuma Y, et al
    Concerns with the new SYNTAX score - Authors' reply.
    Lancet. 2021;397:795-796.
    PubMed    
    
    
    
41. FREEMANTLE N, Pagano D
    Concerns with the new SYNTAX score.
    Lancet. 2021;397:795.
    PubMed    
    
    
    
42. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available
    
    
    January 2021
43. KAURA A, Sterne JAC, Trickey A, Mayet J, et al
    Managing NSTEMI in older patients - Authors' reply.
    Lancet. 2021;397:371-372.
    PubMed    
    
    
    
44. CORDERO A, Rodriguez-Manero M, Bertomeu-Gonzalez V, Gonzalez-Juanatey JR, et al
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370-371.
    PubMed    
    
    
    
45. VERSACI F, Frati G, Biondi-Zoccai G
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370.
    PubMed    
    
    
    
46. D'ASCENZO F, De Filippo O, Gallone G, Mittone G, et al
    Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.
    Lancet. 2021;397:199-207.
    PubMed     Abstract available
    
    
    
47. TEMPLIN C, Di Vece D
    Risk scores in predicting adverse events following acute coronary syndrome.
    Lancet. 2021;397:172-173.
    PubMed    
    
    
    December 2020
48. JACKSON R, Wells S, Rodgers A
    Cardiovascular preventive strategies are not conflicting.
    Lancet. 2020;396:1879-1880.
    PubMed    
    
    
    November 2020
49. RAAL FJ, Mohamed F
    Never too old to benefit from lipid-lowering treatment.
    Lancet. 2020;396:1608-1609.
    PubMed    
    
    
    
50. GENCER B, Marston NA, Im K, Cannon CP, et al
    Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2020;396:1637-1643.
    PubMed     Abstract available
    
    
    
51. SILVAIN J, Lattuca B, Beygui F, Range G, et al
    Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32236.
    PubMed     Abstract available
    
    
    
52. MORTENSEN MB, Nordestgaard BG
    Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort.
    Lancet. 2020 Nov 9. pii: S0140-6736(20)32233.
    PubMed     Abstract available
    
    
    
53. MACKENZIE IS, Ford I, Nuki G, Hallas J, et al
    Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2020 Nov 6. pii: S0140-6736(20)32234.
    PubMed     Abstract available
    
    
    October 2020
54. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32173.
    PubMed     Abstract available
    
    
    
55. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNT
    Lancet. 2020 Oct 8. pii: S0140-6736(20)32114.
    PubMed     Abstract available
    
    
    
56. RAMCHAND J, Burrell LM
    Circulating ACE2: a novel biomarker of cardiovascular risk.
    Lancet. 2020;396:937-939.
    PubMed    
    
    
    September 2020
57. 
    NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: